Cardiovascular outcomes trials for non-cardiac drugs should be “mechanistically sensitive” to the potential safety concerns posed by a particular product and not automatically focused on the traditional endpoint of major ischemic events, cardiology experts on FDA’s Endocrinologic and Metabolic Drugs Advisory Committee agreed.
During the Sept. 11 review of Novo Nordisk AS’ obesity drug Saxenda (liraglutide), University of Colorado cardiologist William Hiatt...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?